Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.
ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.
ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).
The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.
ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.
The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.
Recent Achievements and Current Projects:
- Continued research and development into NAD+ and its related compounds.
- Expansion of Tru Niagen® into new markets globally.
- Ongoing partnerships with leading universities and research institutions.
- Innovative new product launches aimed at further promoting healthy aging.
ChromaDex Corp. (NASDAQ: CDXC) has appointed two new Board members: Kristin Patrick, Chief Marketing Officer of Claire's Inc., and Ann Cohen, CFO of The Institute of Internal Auditors. Patrick has extensive experience in brand strategy from companies like PepsiCo and Playboy, while Cohen brings significant financial expertise from Taylor Morrison Homes and Starwood Vacation Ownership. The company expresses gratitude to departing Board members Jeff Baxter and Caroline Levy, and notes that Kurt Gustafson and Steve Block will not seek re-election at the upcoming annual meeting in June 2022.
ChromaDex (NASDAQ:CDXC) has launched Tru Niagen® Immune, a unique immune health supplement designed to enhance NAD+ levels, vital for aging cells. This product contains a proprietary blend of NAD-boosting Niagen®, vitamins C, D, zinc, and Theracurmin®. NAD+ levels can deplete by up to 80% under immune stress, making this product essential for immune cell function. Retailing at $37.50 for a 30-count bottle, Tru Niagen Immune is now available in the U.S., meeting the growing demand for comprehensive immune support.
ChromaDex Corp. (NASDAQ:CDXC) has been granted a continuation patent, U.S. Patent No. 11,274,117, enhancing its intellectual property for nicotinamide riboside (NR) and other NAD precursors. This patent supports the manufacturing process of NR chloride and new salt forms, crucial for future innovations. With this addition, ChromaDex holds over 40 patents related to Niagen®, its leading product in the healthy aging sector. Both patents expire on November 10, 2037, indicating a strong competitive position in the expanding NAD market.
ChromaDex Corp. (NASDAQ:CDXC) reported fiscal year 2021 net sales of $67.4 million, a 14% increase from 2020, driven by Tru Niagen® sales of $56.7 million. Fourth quarter sales reached $17.8 million, up 15%, while gross margins improved to 61.5%. Despite a net loss of $5.3 million for Q4, the company experienced reduced losses year-over-year. Looking ahead, ChromaDex expects 15-20% revenue growth in 2022, supported by e-commerce and strategic partnerships. The company plans to focus on brand awareness and R&D.
ChromaDex Corp. (NASDAQ:CDXC) announced positive results from a Phase I clinical trial investigating its proprietary ingredient Niagen® in Parkinson’s disease (PD) patients. The study demonstrated a significant increase in cerebral NAD levels and a reduction in inflammatory cytokines. The trial involved 30 newly diagnosed patients, with results indicating improved brain metabolism and mild clinical enhancements. A Phase II study is ongoing, aiming to evaluate NR supplementation in 400 PD patients, thus positioning NR as a potential neuroprotective therapy.
ChromaDex Corp. (NASDAQ:CDXC) will host a conference call on March 9, 2022, at 4:30 p.m. ET, to discuss its Q4 2021 financial results, reported after market hours. The call will also cover general business updates. Interested participants are encouraged to dial in 10 minutes prior to the start time. The conference call can be accessed here and will be available for replay until March 16, 2022.
ChromaDex Corp. (NASDAQ: CDXC) announced the granting of a continuation patent for its key ingredient, Niagen®, a form of nicotinamide riboside (NR). This patent enhances its intellectual property protection, bringing the total to over 40 patents related to NR and NAD precursors. The new U.S. Patent No. 11,242,364, which expires on Nov. 10, 2037, secures the manufacturing processes of NR and its salt forms, supporting potential future innovations. CEO Rob Fried emphasizes the significance of NR in healthy aging.
ChromaDex Corp. (NASDAQ:CDXC) announced results from its 18th clinical trial on Niagen®, a nicotinamide riboside ingredient. Published in the Journal of Clinical Investigation, the study demonstrated that NR supplementation reduces Type-I interferon signaling, which is significant for immune response, particularly in young individuals and lupus patients. Conducted with 35 volunteers, the pilot study supports the potential anti-inflammatory properties of NR, with researchers advocating for further studies on its effects in autoimmune disorders.
FAQ
What is the current stock price of ChromaDex Corporation (CDXC)?
What is the market cap of ChromaDex Corporation (CDXC)?
What is ChromaDex Corporation's main focus?
What is Tru Niagen®?
How does ChromaDex generate most of its revenue?
On which stock exchange is ChromaDex traded?
What are some of ChromaDex's other products?
Who are ChromaDex's research partners?
What is NAD+?
Where can I find more information about ChromaDex?
Does ChromaDex offer services apart from consumer products?
How is ChromaDex contributing to healthy aging research?
